Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Receives Third ApoE Patent

NEW YORK, July 3 – Variagenics was issued a patent for a methodology that links the gene ApoE to a patient’s prognosis with a neurological disorder and the efficacy of various treatments, the company announced Tuesday. 

The patent is the company’s third related to ApoE, the gene that encodes apolipoprotein E, a protein involved in neurological and cardiovascular pathways. Variagenics, based in Cambridge, Mass., expects short-term revenues from this latest patent in the form of collaborative funding from pharmaceutical companies to develop proprietary assays with ApoE for particular drugs, Taylor Crouch, CEO of Variagenics, told GenomeWeb. 

This latest patent will likely solidify Variagenics’s position in the area of neurological disorders, analyst Robert Olan of J.P. Morgan told GenomeWeb, although the business strategy is not new for Variagenics since the company has made it publicly known that it is accumulating intellectual property in this area, Olan added.

Variagenics’s methodology could interest a pharmaceutical company if it believed the information gained from the diagnostic test could benefit the company, by either promoting its products or revealing negative information about its competitors’ products, said Olan. He speculated that some pharmaceutical companies that may be interested in partnering with Variagenics around this technology included Pfizer, J&J, and Elan.

Olan sees pharmacogenomics as being in the early stages of development, and, in terms of revenues, he predicts that Variagenics will most likely have to wait until new and better drugs for neurological disorders appear. “I don’t think that [the impact of this announcement] will be very significant over the next few years,” he said.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.